Photopheresis or extracorporeal photochemotherapy (ECP) is a new immunomodulatory therapy in which a patient’s leukocytes are exposed extracorporeally to 8-methoxypsoralen (8-MOP) and ultraviolet A (UVA) light. Although it is used for the treatment of cutaneous T cell lymphoma, graft-versus-host disease, and several autoimmune diseases, with efficacy and safety reported in almost all studies, the mechanisms by which ECP exerts its beneficial effects are still unclear. As cellular targets of this procedure are numerous, we investigated the effects of 8-MOP and UVA light on stromal precursors and mature stromal layers. Human bone marrow stromal cell layers were established in long-term bone marrow culture medium from normal marrow mononuclear cells. Normal marrow mononuclear cells were incubated with 8-MOP and/or exposed to UVA light (PUVA treatment) before culturing. A control without 8-MOP and UVA was also included in the study. Apoptosis induction was evaluated using annexin V following 7 days after PUVA. After 4–6 weeks of culture, stromal layers were examined under a phase-contrast microscope to identify structural differences between PUVA-treated and control stroma. To determine whether PUVA treatment affected stromal regulation of adherent hematopoietic cell survival, mature stromal layers, incubated with 8-MOP and exposed to UVA light, were cocultured with nonadherent mononuclear cells from normal marrow. After 24 h, the percentage of apoptotic hematopoietic cell precursors was quantified by flow cytometry. This study provides evidences that the in vitro exposure of human stromal cell precursors to UVA light, in the presence of 8-MOP, inhibits stromal layer generation by inducing apoptosis, as evidenced by annexin V staining following 7 days of culture. Here, we show an additional cell target for this psoralen following UVA irradiation. However, in a second set of experiments, PUVA treatment did not affect the stromal capacity to support hematopoiesis in culture. Our results can contribute to a better definition of ECP mechanisms of action for future development of experimental designs and clinical applications of this intriguing procedure.

1.
Zic JA, Miller JL, Stricklin GP, King LE: The North American experience with photopheresis. Ther Apher 1999;3:50–62.
2.
Heshmati F, Andreu G, for the French Group of Extracorporeal Photochemotherapy: Extracorporeal photochemotherapy: a historical perspective. Transfus Apher Sci 2003;28:25–34.
3.
Schooneman F: Extracorporeal photopheresis technical aspects. Transfus Apher Sci 2003;28:51–61.
4.
Zic JA: The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003;6:337–346.
5.
Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P, Krutmann J, Honigsmann H, Ciovica M, Knobler RM: Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998;92:3098–3104.
6.
Dall’Amico R, Murer L: Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci 2002;26:197–204.
7.
Gasparro FP, Dall’Amico R, Goldminz D, Simmons E, Weingold D: Molecular aspects of extracorporeal photochemotherapy. Yale J Biol Med 1989;62:579–593.
8.
Yoo EK, Rook AH, Elenitsas S, Gasparro FP, Vowels BR: Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996;107:235–242.
9.
Legitimo A, Consolini R, Di Stefano R, Bencivelli W, Calleri A, Mosca F: Evaluation of the immunomodulatory effects of photochemotherapy in transplantation. Transplant Proc 2001;33:2266–2268.
10.
Legitimo A, Consolini R, Di Stefano R, Bencivelli W, Mosca F: Psoralen and UVA light: an in vitro investigation of multiple immunological mechanisms underlying the immunosuppression induction in allograft rejection. Blood Cells Mol Dis 2002;29:24–34.
11.
Bladon J, Taylor PC: Extracorporeal photopheresis in cutaneous T-cell lymphoma and graft-versus-host disease induces both immediate and progressive apoptotic processes. Br J Dermatol 2002;146:59–68.
12.
Girardi M, Schechner J, Glusac E, Berger C, Edelson R: Transimmunization and the evolution of extracorporeal photochemotherapy. Transfus Apher Sci 2002;26:181–190.
13.
Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL: Transimmunization, a novel approach for tumor immunotherapy. Transfus Apher Sci 2002;26:205–216.
14.
Heshmati F: Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci 2003;29:61–70.
15.
Gorgun G, Miller KB, Foss FM: Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002;100:941–947.
16.
Fimiani M, Di Renzo M, Rubegni P: Mechanism of action of extracorporeal photochemotherapy in chronic graft-versus-host disease. Br J Dermatol 2004;150:1055–1060.
17.
Tokura Y: Modulation of cytokine production by 8-methoxypsoralen and UVA. J Dermatol Sci 1999;19:114–122.
18.
Craciun LI, Stordeur P, Schandene L, Duvillier H, Bron D, Lambermont M, Goldman M, Dupont E: Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease. Transplantation 2002;74:995–1000.
19.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–147.
20.
Tauro S, Hepburn MD, Bowen DT, Pippard MJ: Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001;86:1038–1045.
21.
Consolini R, Pui CH, Behm FG, Raimondi SC, Campana D: In vitro cytotoxicity of docetaxel in childhood acute leukemias. J Clin Oncol 1998;16:907–913.
22.
Brown DB, Peritz AE, Uitto J, Gasparro FP: Ultraviolet-filtering properties of commonly used tissue cell culture plasticware. Photodermatol Photoimmunol Photomed 2001;17:126–129.
23.
Bladon J, Taylor PC: Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999;107:707–711.
24.
Procaccini EM, Selleri C, Monfrecola G, Camera A, Villa MR, Notaro R, di Grazia C, Posteraro G, Rotoli B: In vitro photoinhibition by psoralen and ultraviolet A radiation of human hematopoietic progenitors. Photodermatol Photoimmunol Photomed 1996;12:200–203.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.